日本血液学会造血与淋巴组织肿瘤指南-白血病：4. 慢性粒细胞白血病（CML）/骨髓增殖性肿瘤（MPN）。 - Suppr

JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).

作者信息

Usui Noriko

机构信息

Department of Transfusion Medicine/Clinical Oncology and Hematology, The Jikei University Daisan Hospital, Komae, Tokyo, 201-8601, Japan.

出版信息

Int J Hematol. 2017 Nov;106(5):591-611. doi: 10.1007/s12185-017-2330-1. Epub 2017 Sep 21.

DOI:10.1007/s12185-017-2330-1

PMID:28936634

Abstract

摘要

相似文献

JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).日本血液学会造血与淋巴组织肿瘤指南-白血病：4. 慢性粒细胞白血病（CML）/骨髓增殖性肿瘤（MPN）。

Int J Hematol. 2017 Nov;106(5):591-611. doi: 10.1007/s12185-017-2330-1. Epub 2017 Sep 21.

JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN).《日本血液学会血液系统恶性肿瘤实用指南（2018年版）：I. 白血病 - 4. 慢性髓性白血病（CML）/骨髓增殖性肿瘤（MPN）》

Int J Hematol. 2020 Sep;112(3):268-291. doi: 10.1007/s12185-020-02964-0. Epub 2020 Aug 11.

Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?酪氨酸激酶抑制剂在慢性髓性白血病中的应用：何时、何地、何种情况下使用？

Nat Rev Clin Oncol. 2017 Mar;14(3):141-154. doi: 10.1038/nrclinonc.2016.139. Epub 2016 Oct 18.

Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors.656例接受第二代和第三代酪氨酸激酶抑制剂治疗的慢性髓性白血病患者的心血管疾病长期死亡率

Int J Cardiol. 2020 Feb 15;301:163-166. doi: 10.1016/j.ijcard.2019.10.036. Epub 2019 Oct 24.

[Chronic myeloid leukemia 2008].[慢性髓性白血病2008年]

Med Clin (Barc). 2008 Nov 15;131(17):658-9. doi: 10.1157/13128730.

Off-Target Effects of BCR-ABL and JAK2 Inhibitors.BCR-ABL和JAK2抑制剂的脱靶效应。

Am J Clin Oncol. 2016 Feb;39(1):76-84. doi: 10.1097/COC.0000000000000023.

[Management of advanced stage chronic myeloid leukemia].[晚期慢性髓性白血病的管理]

Rinsho Ketsueki. 2014 Oct;55(10):1860-9.

Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.使用第二代酪氨酸激酶抑制剂成功治疗并存慢性髓性白血病的滤泡性淋巴瘤。

Int J Hematol. 2018 Jun;107(6):712-715. doi: 10.1007/s12185-017-2378-y. Epub 2017 Nov 28.

Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients.开发用于治疗伊马替尼耐药慢性粒细胞白血病患者的新型酪氨酸激酶抑制剂。

Rinsho Ketsueki. 2009 Jul;50(7):547-55.

Current world literature.当前世界文献。

Curr Opin Hematol. 2011 Mar;18(2):124-31. doi: 10.1097/MOH.0b013e328344622d.

引用本文的文献

Combined Effects of 2-Methoxyestradiol (Hypoxia-Inducible Factor 1 Inhibitor) and Dasatinib (A Second-Generation Tyrosine Kinase Inhibitor) on Chronic Myelocytic Leukemia Cells.2-甲氧基雌二醇（缺氧诱导因子 1 抑制剂）和达沙替尼（第二代酪氨酸激酶抑制剂）联合作用对慢性髓性白血病细胞的影响。

J Immunol Res. 2022 Apr 28;2022:6324326. doi: 10.1155/2022/6324326. eCollection 2022.

The Myeloproliferative Neoplasm Landscape: A Patient's Eye View.骨髓增殖性肿瘤全景：患者视角。

Adv Ther. 2020 May;37(5):2050-2070. doi: 10.1007/s12325-020-01314-0. Epub 2020 Apr 23.

Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients.尼洛替尼治疗的日本慢性髓性白血病患者无治疗缓解的预算影响分析。

Cancer Sci. 2020 Jul;111(7):2526-2535. doi: 10.1111/cas.14430. Epub 2020 May 23.

Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.在真实环境中，阿那格雷作为细胞减少治疗初治原发性血小板增多症患者的一线药物的疗效和安全性。

Eur J Haematol. 2019 Aug;103(2):116-123. doi: 10.1111/ejh.13265. Epub 2019 Jun 17.

Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation.移植前和移植后ponatinib 治疗伴有 T315I 突变的急性巨核细胞白血病原始细胞危象期的慢性髓性白血病患者，该患者接受了异基因造血干细胞移植。

Int J Hematol. 2019 Jul;110(1):119-123. doi: 10.1007/s12185-019-02628-8. Epub 2019 Mar 16.

Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale.通过数字聚合酶链反应分析主要 BCR-ABL1 mRNA 有助于预测国际标准。

Int J Clin Oncol. 2019 Jul;24(7):871-875. doi: 10.1007/s10147-019-01419-9. Epub 2019 Feb 23.

Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia.慢性粒细胞白血病患者长期使用伊马替尼治疗相关的肾功能不全和贫血

Int J Hematol. 2019 Mar;109(3):292-298. doi: 10.1007/s12185-019-02596-z. Epub 2019 Jan 24.

Chronic myelogenous leukemia presenting with central nervous system infiltration, successfully treated with central nervous system-directed chemotherapy followed by allogeneic stem cell transplantation.慢性粒细胞白血病伴中枢神经系统浸润，经中枢神经系统定向化疗后成功治疗，随后进行异基因干细胞移植。

Int J Hematol. 2018 Dec;108(6):640-646. doi: 10.1007/s12185-018-2511-6. Epub 2018 Aug 4.

Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan.真性红细胞增多症和原发性血小板增多症中的血栓出血事件、疾病进展及生存情况：日本宫崎县的一项回顾性调查

Int J Hematol. 2018 Jun;107(6):681-688. doi: 10.1007/s12185-018-2428-0. Epub 2018 Feb 27.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献